Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.8%

53 terminated/withdrawn out of 255 trials

Success Rate

71.5%

-15.1% vs industry average

Late-Stage Pipeline

4%

11 trials in Phase 3/4

Results Transparency

44%

58 of 133 completed trials have results

Key Signals

30 recruiting58 with results36 terminated17 withdrawn

Enrollment Performance

Analytics

N/A
81(35.5%)
Phase 2
78(34.2%)
Phase 1
50(21.9%)
Early Phase 1
8(3.5%)
Phase 3
8(3.5%)
Phase 4
3(1.3%)
228Total
N/A(81)
Phase 2(78)
Phase 1(50)
Early Phase 1(8)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (255)

Showing 20 of 255 trials
NCT07854769Not Yet Recruiting

Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer

Role: lead

NCT06089954Not ApplicableActive Not Recruiting

Penn Medicine Biobank Return of Results Program

Role: collaborator

NCT05274048Phase 1Recruiting

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Role: lead

NCT02968732Not ApplicableActive Not Recruiting

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

Role: lead

NCT06652347Not ApplicableRecruiting

Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning.

Role: lead

NCT04506554Phase 2Active Not Recruiting

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Role: lead

NCT07638410Not ApplicableRecruiting

Prehabilitation in High-risk Oncologic Surgery

Role: lead

NCT05454280Phase 3Active Not Recruiting

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

Role: lead

NCT04827810Phase 1Suspended

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Role: lead

NCT07663422Phase 2Recruiting

Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy

Role: lead

NCT07043972Phase 2Recruiting

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Role: lead

NCT06439706Not ApplicableCompleted

HPV Self-sampling for Underscreened Latinas

Role: lead

NCT06476938Not ApplicableActive Not Recruiting

Testing Gene PilotLX With Latinx Cancer Patients

Role: lead

NCT00902590Active Not Recruiting

A Genotype-Phenotype Urothelial Cancer Registry

Role: collaborator

NCT07776704Not ApplicableRecruiting

Indirect Calorimetry-Guided Parenteral Nutrition Prescribing in Oncology Patients

Role: lead

NCT05393154Completed

Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy

Role: collaborator

NCT04455698Not ApplicableCompleted

Engaging and Activating Cancer Survivors in Genetic Services Study

Role: collaborator

NCT05754658Completed

African Cancer Genome: GMD

Role: lead

NCT07517666Not ApplicableEnrolling By Invitation

Genetic Information for Families After Tumor Testing Study

Role: collaborator

NCT05263050Phase 2Recruiting

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Role: lead